Nabriva Therapeutics (NASDAQ:NBRV) Now Covered by StockNews.com

StockNews.com began coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV) in a research note published on Wednesday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

Nabriva Therapeutics Price Performance

Nabriva Therapeutics has a 12-month low of $1.22 and a 12-month high of $8.45. The company has a current ratio of 0.85, a quick ratio of 0.52 and a debt-to-equity ratio of 0.12. The stock has a market cap of $45.46 million, a PE ratio of -0.07 and a beta of 1.53. The company’s fifty day moving average is $0.14 and its 200-day moving average is $0.61.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Nabriva Therapeutics stock. Renaissance Technologies LLC grew its stake in shares of Nabriva Therapeutics plc (NASDAQ:NBRV) by 102.1% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 795,938 shares of the biotechnology company’s stock after buying an additional 402,144 shares during the period. Renaissance Technologies LLC owned 0.13% of Nabriva Therapeutics worth $145,000 at the end of the most recent reporting period. 0.27% of the stock is currently owned by hedge funds and other institutional investors.

Nabriva Therapeutics Company Profile

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration.